A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes

Details for Australian Patent Application No. 2001273271 (hide)

Owner Metabasis Therapeutics, Inc. Sankyo Company, Limited

Inventors Fujiwara, Toshihiko; Van Poelje, Paul D.; Erion, Mark D

Agent Spruson & Ferguson

Pub. Number AU-B-2001273271

PCT Pub. Number WO02/03978

Priority 60/216,531 06.07.00 US

Filing date 5 July 2001

Wipo publication date 21 January 2002

Acceptance publication date 5 January 2006

International Classifications

A61K 31/00 (2006.01)

Event Publications

5 January 2006 Application Accepted

  Published as AU-B-2001273271

4 May 2006 Standard Patent Sealed

17 July 2008 Assignment Registered

  Sankyo Company, Limited; Metabasis Therapeutics, Inc. The patent has been assigned to Metabasis Therapeutics, Inc.

3 February 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2001273272

2001273270